Description: The MP5-20F3 antibody reacts with mouse interleukin-6 (IL-6). The MP5-20F3 antibody is a neutralizing antibody. Mouse IL-6 (also known as B Cell Stimulating Factor, BCSF, and BSF-2) is a 21-28 kDa factor produced by a variety of cell types, including monocytes, fibroblasts and endothelial cells. Upon stimulation, macrophages, T, B, mast, and glial cells, eosinophils, keratinocytes and granulocytes also secrete IL-6. This pleiotrophic cytokine influences the antigen-specific immune response, inflammatory response, and the development of neurons, and is a major mediator of the acute phase reaction.
Applications Reported: This MP5-20F3 antibody has been reported for use in cytokine neutralization, ELISA capture antibody, and ELISPOT capture antibody.
Applications Tested: The Functional Grade Purified MP5-20F3 antibody has been tested by LAL assay to verify low endotoxin levels, by ELISA, and in bioassay for neutralization of mouse IL-6 bioactivity.
The MP5-20F3 antibody at 0.03 µg/mL has been found to inhibit by 50% the biological effects of 0.01 ng/mL mouse IL-6 in an B9 cell proliferation assay. Detailed information and protocols about can be found in the BestProtocols® section.
The MP5-20F3 antibody has been tested as the capture antibody in a sandwich ELISA for analysis of mouse interleukin-6 (IL-6) in combination with the biotinylated MP5-32C11 (cat. 13-7062) antibody for detection and recombinant mouse IL-6 (cat. 14-8061) as the standard. A suitable range of concentrations of this antibody for ELISA capture is 0.5-2 µg/mL. A standard curve consisting of doubling dilutions of the recombinant standard over the range of 8-1000 pg/mL should be included in each ELISA plate.
Storage and handling: Use in a sterile environment.
Filtration: 0.2 µm post-manufacturing filtered.
Purity: Greater than 90%, as determined by SDS-PAGE.
Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay.
Aggregation: Less than 10%, as determined by HPLC.
Interleukin 6 (IL-6) is a multifunctional 26 kD protein originally discovered in the medium of RNA-stimulated fibroblastoid cells. IL-6 appears to be directly involved in the responses that occur after infection and cellular injury, and it may prove to be important as IL-1 and TNF-a in regulating the acute phase response. IL-6 is reported to be produced by fibroblasts, activated T cells, activated monocytes or macrophages and endothelial cells. IL-6 acts upon a variety of cells including myeloid progenitor cells, T cells, B cells, and hepatocytes. In addition, IL-6 appears to interact with IL-2 in the proliferation of T lymphocytes. IL-6 potentiates the proliferative effect of IL-3 on multipotential hematopoietic progenitors. IL-6 plays a critical role in B-cell differentiation to plasma cells and is a potent growth factor for plasmacytoma and myeloma. IL-6 is a very useful culture supplement for the generation of a high number of antibody-producing hybridomas. Primarily produced at sites of acute and chronic inflammation, IL-6 is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of IL-6 is implicated in a wide variety of inflammation-associated disease states including diabetes mellitus and systemic juvenile rheumatoid arthritis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: B-cell hybridoma growth factor; H-IL-6; IL-6; ILN; Interleukin; Interleukin HP-1; Interleukin-6; Interleukin6; M-IL-6; R-IL-6
Gene Aliases: Il-6; Il6
UniProt ID: (Mouse) P08505
Entrez Gene ID: (Mouse) 16193